We would love to hear your thoughts about our site and services, please take our survey here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Not new, but supports gixer's hypothesis re new blue cap category
http://www.by-health.com/en/aboutus/
Research comprehensively in the cardiovascular health area. We have developed a new product made with Fruitflow®, popularly known as “natural Aspirin”. It helps to maintain normal platelet aggregation;
Your recent posting about the additional Patents in the US can only be good news and can only indicate a potentially growing market on the other side of the pond. TBH I can't understand why this news didn't warrant an RNS.
The initial Abstract posted on the Provexis website on 25th June 2021 seems to indicate that fruitflow could potentially control a wider range of conditions.
The latest two abstracts (one in the UK and one in China) seems to indicate that Fruitflow might have a positive impact in the Covid environment - maybe we might also see some further investigations/trials either in this country or in China and maybe pointing to the anti thrombosis benefits of Fruitflow.
Who knows and as you say - only time will tell.
Hi gixer,
Thanks for the update. Lets hope something will turn up sooner rather than later. All the best for LTH
Slam01,
Thanks.
I just hope that some of my recent posts show that By-Health seem to be spending a lot of time, effort and cash on Fruitflow and its not just a "gimmick" as someone said earlier.
Gixer,
Some of your "research" findings have been amazing and we all have to thank you for that. In all probability they have kept me locked in as a LTH and, at times like now, have even tempted me to by more.
I am not trying to ramp or deramp the Company but some of the recent "stuff" that has been released has been interesting to say the least:
1
DP64 "So what conclusions you made out of all these?"
As I said in my previous post this is just my opinion but would explain the "and they provide strong evidence for
By-Health in its blue cap and other regulatory submissions to the SAMR for Fruitflow" statement in the interim results.
In my opinion By-Health are not only in the process of obtaining Blue Cap for a fruitflow product but also trying to get a new health function into the Health Function Directory.
Did you ask yourself what happened to Provexis market cap in the last few years?
the board should inform the progress and a clear timeline of this partnership heading.
After nearly 5 years since signing the deal with By-Health and their alleged series research studies, there are still no any news to show efforts by By-Health to register any FruitFlow based products in China market. It seems to me that By-Health used the partnership deal, the scientific credentials and series research studies as a gimmick to advance their own purpose of tripling By-Health market capitalisation to current 50 billion Yuan.
Hi gixer,
Thanks for the informative post. So what conclusions you made out of all these?
1/2
With the gradual improvement of national residents' living standards and health awareness, as an important part of the "Healthy China" strategy, it is imperative to conduct research on new functions of health foods.
The new function of health food is a health function that is not within the scope of the current health function published by the State Food and Drug Administration, and is fundamentally different from the name of the current health function and its functional evaluation method.
In order to better meet people's health needs, the Institute integrates the resources of authoritative nutrition and health research institutions at home and abroad, and continuously explores the innovative research field of "new functions, new materials, and new technologies", and has been in the field of new functional products for cardiovascular health. Achieved certain results.
Research Background
In 2009, EFSA approved the first health claim study on "Water-soluble tomato concentrate helps maintain normal platelet aggregation and helps healthy blood flow". This is the first product that has passed the European Food Safety Authority (EFSA) Act 13.5 on the claims of new functions, and has been approved by EFSA's first new health care function. The scientific opinion issued by the European Food Safety Agency (EFSA) in 2011 pointed out that cardiovascular health function claims include adjusting blood lipids, lowering blood pressure, maintaining normal endothelial function, and reducing platelet aggregation. In this scientific opinion, it is pointed out that "in subjects with higher cardiovascular (CV) risk factors (such as smokers, hypercholesterolemia subjects, obesity, diabetes), their platelets are prone to be overactive and hypercoagulable. And it is closely related to the occurrence and development of atherosclerosis and its complications.
In the 2018 China Cardiovascular Disease Risk Assessment and Management Guidelines, increased platelet aggregation has been listed as a potential risk factor for cardiovascular disease. Therefore, the development of different interventions against platelet aggregation has now become a goal of maintaining cardiovascular health. Among them, the research on the new functions of health food in the cardiovascular field has extremely high necessity and feasibility.
2/2
Research progress
In recent years, the company has taken "Fruitflow® (water-soluble tomato concentrate)" as its main direction, focusing on the development of new functional products that help maintain cardiovascular health.
The project brought together domestic authoritative scientific research resources such as the Institute of Chinese Materia Medica of the Chinese Academy of Chinese Medical Sciences and the School of Public Health of Sun Yat-Sen University, and adopted By-Health ® Xinluo Su Tablets (the main functional ingredients are the same as those approved by EFSA, all are water-soluble tomato concentrates). Experimental samples, refer to domestic and foreign literature and methods approved and published by EFSA, and conducted in-depth investigations around related issues, and finally determined to establish a new function of "help maintain normal platelet aggregation and contribute to healthy blood flow". Animal function test evaluation of health food Methods and evaluation methods of the population test.
At present, this method has been repeatedly verified in Beijing Hospital, Peking University Third Hospital, Dongzhimen Hospital of Beijing University of Chinese Medicine, China Academy of Chinese Medical Sciences, Sun Yat-sen University and other domestic research institutions. The test results prove that the method has wide applicability, easy operation and detection. The results are reproducible. The project seeks safer antiplatelet substances to maintain normal platelet aggregation, reduces the risk factors for the occurrence and development of cardiovascular diseases, and makes an effective exploration for the research on new functions of health foods and the profound significance of maintaining public health.
In the future, the Institute will carry out more exploration and research in health areas such as reducing the end-products of glycosylation in the body to meet the health needs of different populations in different life cycles.
By-Health were ready to launch there first Fruitflow product in the second half of 2017 before deciding Blue Cap was the best way to go with it.
Studies in China were then required for Blue Cap submission and the last we were told was that BY-HEALTH were intending to make its first submission to the SAMR for Fruitflow® in February 2019. We all know that Blue Cap registration can be a slow process and the time scale is out with By-Healths control, 2 to 3 years has been quoted in previous info posted on here.
This is were it gets a bit vague . Currently there are 27 health functions in China most of which are not applicable to Fruitflow. One that is is "Assisting blood pressure reduction" and By-Health have a patent for a product that contains fruitflow to facilitate blood pressure reduction.
https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2020077747&_cid=P11-KJGTMR-22408-1
https://patentscope.wipo.int/search/en/detail.jsf?docId=CN238963528&_cid=P11-KJGTMR-22408-1
So a blood pressure reduction product would be a prime candidate (IMO) for the first Blue Cap submission.
We have been told By-Health will launch "a number of Fruitflow based products" but what health function out of the list of 27 can they then use?
In my opinion By-Health are not only in the process of obtaining Blue Cap for a fruitflow product but also trying to get a new health function into the Health Function Directory. What that will be I don't know but something like assisting the reduction of platelet aggregation might open up a lot more opportunities for Fruitflow in China.
All we can do is wait.
It's been nearly 5 years coming this November, since we first started working with byhealth ,still waiting for blue cup approval, its getting frustrating
Again, my reading of this is that the trades rarely take place at the extreme low or high points, but when they do it indicates to me where the next movement will be. With so large a spread there's nothing of interest for short term traders. This causes much lower volumes, meaning the MM's make very little income on trades. Bear in mind that each MM is trading hundreds of different shares, so having no turnover on any particular one doesn't trouble them. You must have noted that they try to anticipate major events such as scheduled updates, probable funding calls etc and move up or down ahead of what they think may happen. In that sense they are acting as traders do. If they have a big buyer, they know that and we don't, so they'll raise the Ask beyond what others want to invest at, and move the Bid around to try to accumulate the shares to fill the buy order. Alternatively, they can fill the order with shares they don't have, then drop the Bid sharply to trigger stops or panic sells. Nasty for us, but all in the game to them. MM's have much more power than PI's except in the case of a strung bull run, when they can be severely embarrassed. The famous case in US is an example, although I suspect that there were a few main actors whipping the gullible in to a frenzy.
I met a guy a while ago who worked in the markets sector for a major bank. He told me that most folks on the inside see PI's as mugs, to be separated from their capital whenever possible. It's for us to decide our actions in light of that knowledge IMHO
Asim Duttaroy new book.
Includes a section on Fruitflow.
https://www.elsevier.com/books/evidence-based-nutrition-and-clinical-evidence-of-bioactive-foods-in-human-health-and-disease/duttaroy/978-0-12-822405-2
32. Cardioprotective properties of water-soluble compounds of Tomato
Alfista,
You have explained the concept very well. However, the thing that I have never understood is the size of the bid offer spread that they use.
For example, the price quoted yesterday was: Bid 0.84 and Offer 1.0. The Bid/Offer spread was 19%. In fact, if you tried to trade yesterday (as I did) you will have noted that the actual trading prices were: Bid 0.84 and Offer 0.95. The actual Bid/Offer spread was 13%. However, I was completely put off trading because I didn;t want to look at an immediate 13% loss in the value of my investment.
Whichever you consider, the Bid/Offer spread that is quoted is still far too high to encourage investors to trade - and for the last week certainly there has been minimum volume whilst the spreads have been that wide.
On the other hand I have plotted significantly higher volumes when the spreads have been tightened.
Surely the MMs job is to encourage volume - they won't make any money unless shares are trading and we won't get a liquid market in the stock until that happens.
Thank you, very well explained
Responding to the headline price shown on here doesn't help your mood, so why not take a moment to study the trades, then you'll see that the sp rose slightly yesterday, due to MM's raising the Bid. At this time, with almost no trades, only the small adjustment non trades, the Bid and Ask are the only indicators of where MM thinking may be. They raised the Bid incrementally last week, keeping the Ask static. You may read this as meaning that they are slightly keener to buy shares than to sell them. MM's can, and do, short shares, hoping to push down the Ask and buy in shares to balance the books over a period. If no-one is selling, they have a problem, and have to raise the Bid. If still no-one sells, they have a real problem, but then they can go long, still without actually owning shares. Very complex, I'd still like to see a definitive cause of all those tiny trades.
All of the studies, and the continued mention of further brand take up, indicate to me that Fruitflow is still in the foothills of global development. I didn't know how long this would take. As far as I can assess, neither did anyone else, including the BoD and DSM/By Health. But we are getting there. IMHO
Thanks, but still pathetic!!
I don't think the bid or ask changed from open so mid is still the same but looks like the UT trade pulled us down.
Up 5.88% on the other side though.
https://www.lse.co.uk/ShareTrades.asp?shareprice=PXS.GB.PL&share=Provexis-Plc
£32.00 sold and SP goes down 8+% ridiculous
Released 2 days ago is hardly stale.
Been spoken about for months